"The Union for International Cancer Control (UICC) unites the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda."
The ICCP Portal is a one-stop stop for cancer prevention and control planning. It hosts topic-specific networks across the cancer care continuum that identifies best practices, key resources and gaps in those fields.
The Expert Committee recommended the addition of dasatinib and nilotinib to the complementary list of the EML for the treatment of chronic myeloid leukaemia that is resistant to imatinib (i.e. second-line therapy).
The Expert Committee did not recommend listing for other proposed cancer medicines: enzalutamide for metastatic breast cancer; tyrosine kinase inhibitors (erlotinib, gefitinib and afatinib) and anaplastic lymphoma kinase (ALK-) inhibitor (crizotinib) for non-small cell lung cancer; trastuzumab emtansine for metastatic breast cancer. The Committee considered that listing of these medicines was premature and recommended the establishment of an EML cancer medicines working group to coordinate comprehensive evaluation of cancer medicines for the EML.
The Expert Committee recommended the formation of expert working groups to support future work for EML reviews and applications. Specifically, a working group for cancer medicines to define criteria and thresholds for prioritization of medicines was recommended.
Wednesday, 14 June 2017 – Today, the Norwegian Cancer Society (NCS), have launched a new campaign calling on other organisations to raise awareness and take action against the threat of antimicrobial resistance (AMR) including antibiotic resistance, which could set cancer treatment back decades.